# US 2022/0016106 A1 · Compounds and methods useful for treating or preventing hematological cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0016106 A1
- Document ID: US20220016106A1
- Status: Published application
- Kind: A1
- Application number: 17/383,161
- Filed: 2021-07-22
- Published: 2022-01-20
- Earliest claimed: 2015-09-01
- Assignees: The Broad Institute, Inc.; The General Hospital Corporation; President and Fellows of Harvard College; Bayer Pharma Aktiengesellschaft
- Applicants: The Broad Institute, Inc.; The General Hospital Corporation; President and Fellows of Harvard College; Bayer Pharma Aktiengesellschaft
- Inventors: David B. Sykes; David Scadden; Timothy A. Lewis; Andreas Janzer; Hanna Meyer; Detlef Stöckigt
- Web page: https://patentgrep.com/patent/US20220016106A1

## CPC

- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/27: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/42: Oxazoles
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 33/36: Arsenic; Compounds thereof
- A61P 35/02: specific for leukemia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention includes methods of treating patients with acute myeloid leukemia across a range of genetic subtypes with DHODH inhibitors, such as 6-fluoro-2-(2′-fluoro-[1,1′-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid).

## Claims

### Claim at position 1

1-11. (canceled)

### Claim 12

A method of treating a hematological cancer in a subject in need thereof comprising:
(a) administering to the subject a first dose of a dihydroorotate dehydrogenase (DHODH) inhibitor;
(b) detecting dihydroorotate (DHO) and/or uridine in a biological sample obtained from the subject; and
(c) administering a second dose of a DHODH inhibitor, wherein the amount and or timing of the administration is modified based on the amounts of DHO and/or uridine detected, thereby treating the hematological malignancy in the subject.

### Claim 13 (depends on 12)

The method according to claim 12 wherein the amount and/or timing of DHODH inhibitor administration is sufficient to increase levels of dihydroorotate by at least about 100-500 fold.

### Claim 14 (depends on 12)

The method according to claim 12, wherein the second dose of DHODH inhibitor is administered after the amount of DHO has returned to baseline.

### Claim 15 (depends on 12)

The method according to claim 12, wherein the method comprises:
(a) administering to the subject a first dose of 6-fluoro-2-(2′-fluoro-[1,1′-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid, or a salt or solvate thereof;
(b) detecting DHO and/or uridine in a biological sample obtained from the subject; and
(c) administering a second dose of 6-fluoro-2-(2′-fluoro-[1,1′-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid), or a salt or solvate thereof, wherein the amount and/or timing of the administration is modified based on the amounts of DHO and/or uridine detected, thereby treating the hematological cancer in the subject.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the second dose of DHODH inhibitor is administered after the amount of DHO has returned to baseline.

### Claim 17 (depends on 12)

The method according to claim 12, wherein the second dose is administered when the amount of uridine is 10-25% greater than the level of uridine present 12 hours after administration of the first dose.
